MarketPulse

pharmaceutical companies

7 articles
The Motley FoolThe Motley Fool··Eric Volkman

Healthcare's Dividend Gems: Why $ABBV and $BMY Stand Out for Income Investors

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.
BMYCELGrABBVABTdividend stocksdividend growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Sub-$50 Healthcare Stocks Poised for Growth in Pharma, Oncology Sectors

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.
PFENVOEXELvaluationbiotech
BenzingaBenzinga··Namrata Sen

Amgen, GSK Join TrumpRx Platform With Deep Discounts as Drug Pricing Pressure Mounts

Amgen and GSK join TrumpRx.gov offering up to 80% and 10-55% discounts respectively, expanding the platform to 54 drugs amid Trump administration pricing pressure.
AMGNPFELLYNVOAZN+1pharmaceutical companiesdrug affordability
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Lilly's Valuation Trap vs. Merck's Dividend Appeal: A Tale of Two Pharma Giants

Eli Lilly trades at expensive P/E of 44 with meager 0.6% dividend yield despite GLP-1 success. Merck offers better value at P/E 16 and 2.8% yield with 30+ year dividend track record.
MRKLLYvaluationdividend stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer's Boring Appeal: Why Blue-Chip Stability Beats Biotech Hype

Pfizer's reasonable valuation, robust pipeline, and 6.4% dividend yield offer disciplined returns versus speculative biotech like Regencell, whose 21,000% surge lacks fundamental justification.
PFERGCstock valuationclinical trials
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Bristol Myers Squibb's 4% Dividend Could Compound to Seven-Figure Wealth

Bristol Myers Squibb's 4% dividend yield, well above sector averages and trading 25% below 2022 highs, could compound into seven-figure retirement wealth through consistent reinvestment.
BMYCELGrdividend stocksdividend yield
The Motley FoolThe Motley Fool··Dave Kovaleski

Healthcare Giants Offer Defensive Appeal Amid Market Correction Concerns

Investors anticipate 2026 market volatility, driving interest in defensive healthcare stocks. AbbVie and Merck offer stable dividends and historical resilience during downturns.
MRKABBVdividend stocksdividend yield